Woodline Partners’s Climb Bio CLYM Stock Holding History
Bought
Maintained
Sold
Other funds holding CLYM
Woodline Partners's CLYM Position: Q3 2026 in Review
Woodline Partners increased its Climb Bio (CLYM) stake by 73% in Q3 2026, buying an estimated $16M and bringing the position to 2,731,469 shares worth $31.3M. The position accounts for 0.09% of the portfolio, ranked #284.
Woodline Partners first reported a position in CLYM in Q3 2021 and has held it in 8 quarters since. 128 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.
- Woodline Partners held 2,731,469 shares of Climb Bio worth $31.3M as of Q3 2026.
- Woodline Partners bought 1,149,178 Climb Bio shares in Q3 2026, an estimated $16M.
- Climb Bio made up 0.09% of Woodline Partners's portfolio in Q3 2026, its #284 holding.
- Woodline Partners first reported a position in Climb Bio in Q3 2021 and has held it in 8 quarters since.
- 128 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.